Tag: Multiple Myeloma
Study Supports Minimal Residual Disease As End Point in Myeloma
MRD-negative status linked to favorable progression-free, overall survival in multiple myeloma
Survival Up With Daratumumab in Relapsed Multiple Myeloma
Longer progression-free survival seen with daratumumab plus bortezomib and dexamethasone
